🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "major milestone" in the battle against drug-resistant strains of the infection, according to scientists.

A Global Public Health Issue

The sexually transmitted infection are increasing globally, with estimates suggesting over 82 million new cases per year. Notably increased rates are seen in the African continent and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune development in the reality of increasing worldwide cases, the spread of superbugs and the very limited available drugs at this time.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring found that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the American regulatory agency in mid-December for combating gonorrhoea. This disease can lead to significant complications, including infertility. Experts believe that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in close succession. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin emerged from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This authorization signifies a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Research Study Data and Worldwide Availability

Based on findings detailed in a major medical journal, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the existing first-line therapy, which uses two antibiotics. The study involved nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have voiced optimism. Having a one-pill regimen of this kind is seen as a "critical tool" for gonorrhoea control. This is considered vital to alleviate the strain of the illness for patients and to stop the proliferation of extremely resistant gonorrhoea around the world.